Latest news
{{'2026-09-18T10:36:39Z' | dateFormatFilter}}
Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
{{'2026-09-17T14:14:35Z' | dateFormatFilter}}
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
{{'2026-09-17T11:01:28Z' | dateFormatFilter}}
Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
